Becton, Dickinson and Company (NYSE:BDX) Shares Sold by RWA Wealth Partners LLC

RWA Wealth Partners LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,700 shares of the medical instruments supplier’s stock after selling 400 shares during the quarter. RWA Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $3,335,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Bank of Jackson Hole Trust purchased a new position in Becton, Dickinson and Company in the 4th quarter valued at $25,000. Sierra Ocean LLC purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter worth about $29,000. Picton Mahoney Asset Management boosted its position in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 54 shares during the last quarter. Hopwood Financial Services Inc. purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at about $39,000. Finally, Versant Capital Management Inc raised its holdings in Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 73 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Becton, Dickinson and Company news, Director Jeffrey William Henderson purchased 1,500 shares of the company’s stock in a transaction on Monday, February 10th. The stock was acquired at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the purchase, the director now directly owns 8,015 shares in the company, valued at approximately $1,872,464.30. The trade was a 23.02 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard Byrd sold 459 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the sale, the executive vice president now owns 6,952 shares in the company, valued at approximately $1,598,960. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on BDX shares. Barclays boosted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Tuesday, March 25th. Finally, Piper Sandler lifted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $278.29.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $227.34 on Monday. The stock has a market cap of $65.28 billion, a PE ratio of 37.76, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The stock has a fifty day simple moving average of $231.83 and a 200-day simple moving average of $231.72. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.10%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.